Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 5/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473012 | 0.82 | FDPS (0.47) | CA2MAPK1FDPSGPR84FFAR1 | |
| SCHEMBL3232568 | 0.81 | FOLH1 (0.57) | CA2MAPK1FDPSGPR84FFAR1 | |
| SCHEMBL2991458 | 0.81 | FDPS (0.50) | CA2MAPK1FDPSGPR84FFAR1 | |
| SCHEMBL3471395 | 0.78 | FOLH1 (0.37) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL389804 | 0.75 | FDPS (0.57) | FDPSGPR84FFAR1MAPTLCK | |
| SCHEMBL2989636 | 0.75 | CA2 (0.47) | CA2MAPK1FDPSGPR84FFAR1 | |
| SCHEMBL9841018 | 0.73 | FDPS (0.59) | FDPSGPR84FFAR1MAPTLCK | |
| SCHEMBL9487038 | 0.73 | FDPS (0.59) | FDPSGPR84FFAR1MAPTLCK | |
| SCHEMBL3377184 | 0.73 | FDPS (0.59) | FDPSGPR84FFAR1MAPTLCK | |
| SCHEMBL2023917 | 0.73 | FDPS (0.59) | FDPSGPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125029-B1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | MDRNA RESEARCH, INC. | 2010-01-28 | — | — | US | disclosed |
| EP-0792275-B1 | IMPROVED ANTIVIRAL PRODRUGS | UNIV CALIFORNIA (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6002029-A | Antiviral prodrugs | CHIMERIX, INC. | 1999-12-14 | — | — | US | disclosed |
| EP-0792275-A4 | IMPROVED ANTIVIRAL PRODRUGS | UNIV CALIFORNIA (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5696277-A | CYTOMEGALOVIRUS, HERPES VIRUS | Hostetler, Karl Y. (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0792275-A1 | IMPROVED ANTIVIRAL PRODRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996015132-A1 | IMPROVED ANTIVIRAL PRODRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | CA2 611/4885MAPK1 1640/4885FDPS 3321/4885 |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | CA2 611/4885MAPK1 1640/4885FDPS 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.